Education
About Us
Working with TipRanks
Follow Us
Elicera Therapeutics AB (SE:ELIC)
:ELIC
ELIC Stock Chart & Stats
kr5.35
kr0.03(1.27%)
At close: 4:00 PM EST
kr5.35
kr0.03(1.27%)
Day’s Range― - ―
52-Week Rangekr2.05 - kr8.43
Previous CloseN/A
Volume204.65K
Average Volume (3M)134.24K
Market Cap
kr228.12M
Enterprise Valuekr193.19M
Total Cash (Recent Filing)kr34.92M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.44
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,535,545
10 Day Avg. Volume92,396
30 Day Avg. Volume134,243
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.54
Price to Sales (P/S)7.40
P/FCF Ratio-2.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ELIC FAQ
What was Elicera Therapeutics AB’s price range in the past 12 months?
Elicera Therapeutics AB lowest stock price was kr2.05 and its highest was kr8.43 in the past 12 months.
What is Elicera Therapeutics AB’s market cap?
Elicera Therapeutics AB’s market cap is kr228.12M.
When is Elicera Therapeutics AB’s upcoming earnings report date?
Elicera Therapeutics AB’s upcoming earnings report date is Apr 28, 2026 which is in 72 days.
How were Elicera Therapeutics AB’s earnings last quarter?
Currently, no data Available
Is Elicera Therapeutics AB overvalued?
According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued.
Does Elicera Therapeutics AB pay dividends?
Elicera Therapeutics AB does not currently pay dividends.
What is Elicera Therapeutics AB’s EPS estimate?
Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicera Therapeutics AB have?
Elicera Therapeutics AB has 48,535,545 shares outstanding.
What happened to Elicera Therapeutics AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Elicera Therapeutics AB?
Currently, no hedge funds are holding shares in SE:ELIC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
Technical Analysis
Isofol Medical AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―